Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients

Small tumor size (≤5 mm, T1a) carries an excellent prognosis. Controversy exists over the extent of the variety of treatment approaches. We therefore explored the effect of adjuvant systemic therapy (AST) on recurrence free survival (RFS) and overall survival (OAS) for the group of T1a-tumors. Metho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Archives of gynecology and obstetrics 2016-08, Vol.294 (2), p.377-384
Hauptverfasser:	Wolters, R., Ebner, F., Janni, W., Novopashenny, I., Wöckel, A., Kreienberg, R., Wischnewsky, M., Schwentner, Lukas
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic Agents - therapeutic use Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - mortality Breast Neoplasms - pathology Chemotherapy, Adjuvant Cohort analysis Combined Modality Therapy Disease-Free Survival Endocrinology Female Gynecologic Oncology Gynecology Human Genetics Humans Medical prognosis Medicine Medicine & Public Health Middle Aged Obstetrics/Perinatology/Midwifery Prognosis Retrospective Studies Treatment Outcome Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!